Cancer Disparities by Race: What Research Shows About Unequal Outcomes

Racial and ethnic disparities in cancer incidence, stage at diagnosis, treatment access, and mortality have been documented extensively in the United States over the past several decades. Black Americans experience higher cancer mortality rates than white Americans for most major cancer types, including colorectal, prostate, breast, lung, and cervical cancer. These disparities are not inevitable or immutable but reflect a combination of social, economic, biological, and healthcare system factors that research has worked to disentangle. Understanding these causes is essential for designing interventions that can meaningfully narrow the gap. Breast cancer illustrates the complexity of racial cancer disparities. Black women have a slightly lower incidence of breast cancer than white women overall but have significantly higher mortality rates. This mortality disparity reflects multiple contributing factors. Black women are more likely to be diagnosed at late stages when treatment is less effective, partly reflecting barriers to screening and follow-up. They are more likely to be diagnosed with triple-negative breast cancer, an aggressive subtype with fewer targeted treatment options, at higher rates than white women. They experience disparities in the receipt of guideline-concordant treatment. And they face barriers to participation in clinical trials that test new therapies. Research on each of these contributing factors provides targets for intervention. Prostate cancer presents a different pattern. Black men are diagnosed with prostate cancer at higher rates and die from it at approximately twice the rate of white men. Research on biological factors finds differences in tumor biology, including more aggressive subtypes at diagnosis, that contribute to worse outcomes independently of stage at diagnosis and treatment. Research on disparities in PSA screening access and follow-up care finds that healthcare access barriers contribute additionally. Understanding the relative contributions of biological and social factors is important for designing interventions that address the right targets. Colorectal cancer screening is one of the most powerful tools for reducing cancer mortality, yet Black Americans are screened at lower rates than white Americans and are diagnosed at later stages on average. Research on barriers to colorectal cancer screening finds that lack of insurance, cost sharing, mistrust of the healthcare system, logistical barriers, and provider communication are all contributing factors. Studies of screening outreach interventions that address these barriers, including patient navigation programs, mailed testing kits, and community health worker outreach, find significant improvements in screening rates among Black populations. Patient navigation programs, which provide individuals with personalized support to navigate the healthcare system from screening through treatment completion, have been evaluated in rigorous studies and found effective at reducing disparities in cancer screening completion and follow-up. These programs are most effective when navigators share cultural backgrounds with the patients they serve and have deep familiarity with local healthcare resources and barriers. Research on navigator effectiveness finds that the relationship between patient and navigator, not simply the logistical support provided, is a critical component of the intervention. Healthcare provider bias, including implicit bias, contributes to racial disparities in cancer care at multiple decision points. Studies of provider-patient interaction find racial differences in communication quality, the provision of clinical information, and adherence to treatment guidelines that disadvantage Black patients. Research on implicit bias training for healthcare providers finds mixed evidence of effectiveness in changing behavior, suggesting that structural changes in how care is delivered may be more effective than individual bias training alone. Clinical trial participation by racial and ethnic minority patients is significantly lower than their share of the cancer burden would warrant. Research on barriers to trial participation finds that exclusion criteria that screen out patients with common comorbidities disproportionately exclude Black patients, that trial recruitment occurs primarily in academic medical centers with lower diversity than the overall population, and that historical research ethics abuses have produced justified distrust that reduces willingness to participate. Expanding trial diversity is both an equity goal and a scientific one, as findings from racially homogeneous trials may not generalize to all populations. Genetics and biology contribute to some racial cancer disparities, but research emphasizes that social and environmental factors are primary drivers. The genetic variation that exists within racial groups is larger than variation between them, and race is a social category rather than a precise biological one. Research on tumor genomics finds some differences in mutational profiles across populations that partially explain outcome differences, but environmental exposures, healthcare access, and socioeconomic factors explain more of the disparity than biological factors alone. Closing racial disparities in cancer outcomes requires action across multiple fronts: expanding insurance coverage and removing financial barriers to screening and treatment, training and deploying patient navigators who can support patients through complex healthcare encounters, addressing implicit bias in clinical settings, diversifying clinical trial populations, and investigating the biological dimensions of disparity that require targeted therapeutic development. Research provides the evidence base for each of these interventions; the challenge is translating evidence into action at the scale necessary to produce population-level change.